500 related articles for article (PubMed ID: 29145955)
1. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2.
Chang HM; Okwuosa TM; Scarabelli T; Moudgil R; Yeh ETH
J Am Coll Cardiol; 2017 Nov; 70(20):2552-2565. PubMed ID: 29145955
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1.
Chang HM; Moudgil R; Scarabelli T; Okwuosa TM; Yeh ETH
J Am Coll Cardiol; 2017 Nov; 70(20):2536-2551. PubMed ID: 29145954
[TBL] [Abstract][Full Text] [Related]
3. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management.
Curigliano G; Cardinale D; Dent S; Criscitiello C; Aseyev O; Lenihan D; Cipolla CM
CA Cancer J Clin; 2016 Jul; 66(4):309-25. PubMed ID: 26919165
[TBL] [Abstract][Full Text] [Related]
4. Role of Cardiovascular Biomarkers in the Risk Stratification, Monitoring, and Management of Patients with Cancer.
Hoeger CW; Hayek SS
Cardiol Clin; 2019 Nov; 37(4):505-523. PubMed ID: 31587791
[TBL] [Abstract][Full Text] [Related]
5. Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review.
Porta-Sánchez A; Gilbert C; Spears D; Amir E; Chan J; Nanthakumar K; Thavendiranathan P
J Am Heart Assoc; 2017 Dec; 6(12):. PubMed ID: 29217664
[TBL] [Abstract][Full Text] [Related]
6. Cardio-oncological management of patients.
Cardinale DM; Barac A; Torbicki A; Khandheria BK; Lenihan D; Minotti G
Semin Oncol; 2019 Dec; 46(6):408-413. PubMed ID: 31784042
[TBL] [Abstract][Full Text] [Related]
7. Management of QT prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for different drugs.
Coppola C; Rienzo A; Piscopo G; Barbieri A; Arra C; Maurea N
Cancer Treat Rev; 2018 Feb; 63():135-143. PubMed ID: 29304463
[TBL] [Abstract][Full Text] [Related]
8. The Growing Impact of Cardiovascular Oncology: Epidemiology and Pathophysiology.
Tufano A; Coppola A; Galderisi M
Semin Thromb Hemost; 2021 Nov; 47(8):899-906. PubMed ID: 34255338
[TBL] [Abstract][Full Text] [Related]
9. Radiation-Induced Cardiovascular Disease: Mechanisms, Prevention, and Treatment.
Koutroumpakis E; Deswal A; Yusuf SW; Abe JI; Nead KT; Potter AS; Liao Z; Lin SH; Palaskas NL
Curr Oncol Rep; 2022 May; 24(5):543-553. PubMed ID: 35192118
[TBL] [Abstract][Full Text] [Related]
10. Prospective surveillance and management of cardiac toxicity and health in breast cancer survivors.
Schmitz KH; Prosnitz RG; Schwartz AL; Carver JR
Cancer; 2012 Apr; 118(8 Suppl):2270-6. PubMed ID: 22488701
[TBL] [Abstract][Full Text] [Related]
11. Radiation-Induced Cardiovascular Disease.
Raghunathan D; Khilji MI; Hassan SA; Yusuf SW
Curr Atheroscler Rep; 2017 May; 19(5):22. PubMed ID: 28315200
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular complications after radiotherapy.
Nabiałek-Trojanowska I; Lewicka E; Wrona A; Kaleta AM; Lewicka-Potocka Z; Raczak G; Dziadziuszko R
Cardiol J; 2020; 27(6):836-847. PubMed ID: 30338841
[TBL] [Abstract][Full Text] [Related]
13. [Summary of the ESC position paper on cancer treatment and cardiovascular toxicity].
Hoog J; Achenbach S
Herz; 2016 Dec; 41(8):684-689. PubMed ID: 27830273
[TBL] [Abstract][Full Text] [Related]
14. Hypertension and QT interval prolongation associated with targeted systemic cancer therapies.
Fahey OG; Piccolo JK; Bergsbaken JJ; N Dow-Hillgartner E
J Oncol Pharm Pract; 2020 Dec; 26(8):1987-1996. PubMed ID: 32951523
[TBL] [Abstract][Full Text] [Related]
15. Treatment of cardiovascular diseases in cancer patients.
Noutsias M; Maisch B
Herz; 2011 Jun; 36(4):340-5. PubMed ID: 21584714
[TBL] [Abstract][Full Text] [Related]
16. Recognition, Prevention, and Management of Arrhythmias and Autonomic Disorders in Cardio-Oncology: A Scientific Statement From the American Heart Association.
Fradley MG; Beckie TM; Brown SA; Cheng RK; Dent SF; Nohria A; Patton KK; Singh JP; Olshansky B
Circulation; 2021 Jul; 144(3):e41-e55. PubMed ID: 34134525
[TBL] [Abstract][Full Text] [Related]
17. Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy.
Virani SA; Dent S; Brezden-Masley C; Clarke B; Davis MK; Jassal DS; Johnson C; Lemieux J; Paterson I; Sebag IA; Simmons C; Sulpher J; Thain K; Thavendiranathan P; Wentzell JR; Wurtele N; Côté MA; Fine NM; Haddad H; Hayley BD; Hopkins S; Joy AA; Rayson D; Stadnick E; Straatman L
Can J Cardiol; 2016 Jul; 32(7):831-41. PubMed ID: 27343741
[TBL] [Abstract][Full Text] [Related]
18. Pathology of radiation and anthracycline cardiotoxicity.
Berry GJ; Jorden M
Pediatr Blood Cancer; 2005 Jun; 44(7):630-7. PubMed ID: 15825155
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval).
Shah RR; Morganroth J; Shah DR
Drug Saf; 2013 May; 36(5):295-316. PubMed ID: 23620167
[TBL] [Abstract][Full Text] [Related]
20. Management of cardiovascular risk in patients with multiple myeloma.
Plummer C; Driessen C; Szabo Z; Mateos MV
Blood Cancer J; 2019 Feb; 9(3):26. PubMed ID: 30808934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
